Supreme Court extends mifepristone deadline - Takeaways - MDSpire

Supreme Court extends mifepristone deadline

  • By

  • Theresa Gaffney

  • May 12, 2026

  • 0 min

Share

  • 1

    The Supreme Court has extended the deadline for mifepristone availability by three days amid ongoing legal challenges.

  • 2

    Mifepristone will remain accessible through mail and pharmacies after telehealth appointments until at least Thursday.

  • 3

    Experts have renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to reflect its complexities.

  • 4

    Alcohol-related deaths in the U.S. exceed 178,000 annually, yet it remains under-addressed as a public health crisis.

  • 5

    The FDA has relaxed enforcement on illegal e-cigarette sales, allowing manufacturers to avoid penalties under certain conditions.

Original Source(s)

Supreme Court extends mifepristone deadline

  • by Theresa Gaffney

  • May 12, 2026

Related Content

The impact of daily steps on polycystic ovary syndrome patients

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

PCOS Renamed PMOS After Global Consensus

International initiative reframes a common endocrine disorder around its metabolic and ovarian features rather than ovarian cysts